Advertisement
Australia markets close in 4 hours 29 minutes
  • ALL ORDS

    8,038.00
    +35.20 (+0.44%)
     
  • ASX 200

    7,796.50
    +36.90 (+0.48%)
     
  • AUD/USD

    0.6629
    -0.0022 (-0.34%)
     
  • OIL

    82.07
    +0.33 (+0.40%)
     
  • GOLD

    2,331.20
    -5.40 (-0.23%)
     
  • Bitcoin AUD

    93,741.13
    +1,604.66 (+1.74%)
     
  • CMC Crypto 200

    1,292.01
    +25.87 (+2.04%)
     
  • AUD/EUR

    0.6200
    -0.0006 (-0.10%)
     
  • AUD/NZD

    1.0925
    -0.0002 (-0.02%)
     
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NASDAQ

    19,789.03
    +37.98 (+0.19%)
     
  • FTSE

    8,179.68
    -45.65 (-0.55%)
     
  • Dow Jones

    39,164.06
    +36.26 (+0.09%)
     
  • DAX

    18,210.55
    +55.31 (+0.30%)
     
  • Hang Seng

    17,583.19
    -133.28 (-0.75%)
     
  • NIKKEI 225

    39,741.11
    +399.57 (+1.02%)
     

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

CARLSBAD, Calif., June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.

Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)
Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

A live webcast of this presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

ADVERTISEMENT

To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – ir@ionis.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffermedia@ionis.com – 760-603-4679

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-td-cowen-genetic-medicines--rna-summit-302174669.html

SOURCE Ionis Pharmaceuticals, Inc.